To continue using a Savings Card in 2025, eligible patients can download now under the Savings & Support Page.

Retevmo^®

Now in Tablet Form with Four Dose Strengths

Discover Head-to-Head Data for Retevmo versus First-Line Standards of Care and Find Original Phase I/II Trial Results

Retevmo: where precision and strength meet

Retevmo: The first precision oncology treatment approved by the FDA for certain RET-driven solid tumors, regardless of type^1,2

Selpercatinib (Retevmo) is a National Comprehensive Cancer Network^® (NCCN^®)-recommended treatment option for certain patients with RET-positive metastatic non-small cell lung cancer (NSCLC) and RET-positive advanced or metastatic thyroid carcinoma^3,4*

^*See the NCCN Guidelines for NSCLC for detailed recommendations, including other preferred treatment options.

See NCCN Guidelines^® recommendations

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

The clinical data for Retevmo were from LIBRETTO-001, a phase I/II, multicohort, open-label, single-arm clinical trial.^1,5

Click here to explore clinical trial design.

All results reviewed by an independent review committee (IRC).^1,6-9

Retevmo demonstrated a robust and durable response in certain RET-driven cancers¹

In treatment-naive patients with locally advanced or metastatic RET fusion-positive NSCLC (n=69)¹:

ORR was defined at CR+PR and was assessed by IRC according to RECIST v1.1.¹

Median DoR 20.2 months (95% CI: 13, NE)¹

Median follow-up: 20.3 months¹⁰

In patients previously treated^† with platinum chemotherapy with locally advanced or metastatic RET fusion-positive NSCLC (n-247)¹:

Median DoR 28.6 months (95% CI: 20, NE)¹

Median follow-up: 21.2 months¹⁰

In systemic therapy-naive^‡ patients with advanced or metastatic RET fusion-positive thyroid cancer (non-medullary thyroid cancer (non-MTC))^§ (n=24)¹:

96% ORR (95% CI: 79, 100) 21% CR + 75% PR in green text

Median duration of response (DoR) was not yet reached (95% CI: 42.8, NE) among systemic therapy-naive^‡ patients with advanced or metastatic RET fusion-positive thyroid cancer (non-MTC).^§1

In previously treated^ǁ patients with advanced or metastatic RET fusion-positive thyroid cancer (non-MTC) (n=41)^§1:

85% ORR (95% CI: 71, 94) 12% CR + 73% PR

Median DoR 26.7 months (95% CI: 12.1, NE)¹

In cabozantinib/vandetanib treatment-naive patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) (n=88)¹:

73% objective response rate ORR for cabozantinib/vandetanib treatment-naïve patients with advanced or metastatic RET-mutant medullary thyroid cancer

Median DoR 22.0 months (95% CI: NE, NE)¹

Median follow-up: 7.8 months⁹

In patients previously treated^¶ with cabozantinib and/or vandetanib with advanced or metastatic RET-mutant MTC (n=55)¹:

69% objective response rate ORR for patients previously treated with cabozantiniband or vandetanib with advanced or metastatic RET-mutant medullary thyroid cancer

Median DoR not yet reached (95% CI: 19.1, NE)¹

Median follow-up: 14.1 months⁹

ORR was defined as CR + PR and was assessed by IRC according to RECIST v1.1.¹

In adult patients with other RET-driven solid tumor types (tumor agnostic, n=41)^1#:

Median DoR 24.5 months (95% CI: 9.2, NE)¹

Median follow-up: 14.9 months¹¹

At the time of analysis (September 24, 2021), 50% of responses (n=9/18) were ongoing.¹¹

The major efficacy outcome measures in LIBRETTO-001 were ORR and DoR.

All results reviewed by an IRC.¹

Take action on RET. First, test. Then treat.

Select Important Safety Information

The labeling for Retevmo contains Warnings and Precautions for hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome (TLS), risk of impaired wound healing, hypothyroidism, embryo-fetal toxicity, and slipped capital femoral epiphysis/slipped upper femoral epiphysis (SCFE/SUFE) in pediatric patients.

Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to initiating Retevmo, every 2 weeks during the first 3 months of treatment, then monthly thereafter and as clinically indicated. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly, and as clinically indicated. Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Permanently discontinue Retevmo in patients with severe or life-threatening hemorrhage. If hypersensitivity occurs, withhold Retevmo and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). See full Prescribing Information for further management instructions and dosage modifications for adverse reactions. Closely monitor patients that may be at risk of TLS (rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration) and consider appropriate prophylaxis including hydration. Withhold Retevmo for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. Monitor thyroid function before and periodically during treatment with Retevmo. Withhold until clinically stable or permanently discontinue Retevmo based on severity of hypothyroidism. Based on data from animal reproduction studies and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman. Advise females and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for at least 1 week after the last dose. Monitor patients for symptoms indicative of SCFE/SUFE and treat as medically and surgically appropriate. IN LIBRETTO-001: Serious adverse reactions occurred in 44% of patients who received Retevmo. The most frequent serious adverse reactions (in ≥2% of patients) were pneumonia, pleural effusion, abdominal pain, hemorrhage, hypersensitivity, dyspnea, and hyponatremia. Fatal adverse reactions occurred in 3% of patients; fatal adverse reactions included sepsis (n=6), respiratory failure (n=5), hemorrhage (n=4), pneumonia (n=3), pneumonitis (n=2), cardiac arrest (n=2), sudden death (n=1), and cardiac failure (n=1). Most common adverse reactions (≥25%) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache. Most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), decreased sodium, and decreased calcium.

LIBRETTO-001 Trial Design

The phase I/II, multicohort, open-label, single-arm, multicenter LIBRETTO-001 trial evaluated Retevmo in patients with RET-altered advanced solid tumors. The pooled safety population included the following patients (n=796): advanced or metastatic RET fusion-positive NSCLC^**, advanced or metastatic RET fusion-positive thyroid cancer (non-MTC), advanced or metastatic RET-mutant MTC, the tumor agnostic cohort of other locally advanced or metastatic RET-fusion positive tumors, including pancreatic and CRC^††. Additionally, the overall safety analysis included patients with other cancers, including cancers without a RET alteration. The study evaluated the following cohorts for efficacy: systemic therapy-naive patients (n=69) and previously treated patients who had progressed on platinum-based chemotherapy (n=247^†) with advanced or metastatic RET fusion-positive NSCLC; systemic therapy-naive (n=24^{‡‡§§‡}) and previously treated (n=41^{‡‡§§‖}) patients with advanced or metastatic RET fusion-positive thyroid cancer (non-MTC); patients with advanced or metastatic RET-mutant MTC that were cabozantinib and vandetanib-naive (n=88^§§) and patients previously treated with cabozantinib and vandetanib (n=55^§§¶), and patients in the tumor agnostic cohort (n=41^‖‖). Major efficacy outcomes were ORR and DoR. Other efficacy outcomes included CNS ORR, CNS DoR, PFS, OS, time to response, and best change in tumor size from baseline. In phase II, the dose for Retevmo was 160 mg PO BID.^1,5,10

^†Efficacy was evaluated in 247 adult patients with advanced or metastatic RET fusion-positive NSCLC who were previously treated with platinum chemotherapy enrolled into a cohort of LIBRETTO-001. All 247 patients received systemic therapy (with a median of 2 prior systemic regimens). 144 of the 247 patients received prior anti-PD-1/PD-L1 therapy, and 85 of the 247 patients received a prior MKI.¹⁰
^‡Patients in this cohort received no prior systemic therapy other than radioactive iodine (RAI).¹
^§Primary tumor histologies included papillary thyroid cancer, poorly differentiated thyroid cancer, anaplastic thyroid cancer, and Hurthle cell thyroid cancer.¹
^‖Patients in this cohort received a prior systemic therapy other than RAI.¹
^¶The efficacy of Retevmo was evaluated in 55 patients with RET-mutant advanced MTC who were previously treated with cabozantinib or vandetanib enrolled into a cohort of LIBRETTO-001.¹
^#Efficacy was evaluated in 41 adult patients with advanced or metastatic RET fusion-positive solid tumors. Thirty-seven patients received systemic therapy (with a median of 2 prior systemic regimens).¹
^**Patients with advanced or metastatic RET fusion-positive NSCLC who had progressed on platinum-based chemotherapy and those without prior systemic therapy were enrolled in separate cohorts.¹
^††Efficacy was evaluated in 41 patients, including those with the following tumor types: pancreatic adenocarcinoma (n=11); colorectal (n=10); salivary (n=4); unknown primary (n=3); breast (n=2); sarcoma (soft tissue) (n=2); xanthogranuloma (n=2); carcinoid (bronchial) (n=1); carcinoma of the skin (n=1); cholangiocarcinoma (n=1); ovarian (n=1); pulmonary carcinosarcoma (n=1); rectal neuroendocrine (n=1); small intestine (n=1).¹
^‡‡Non-MTC by histology included papillary (n=54), poorly differentiated (n=6), anaplastic (n=4), and Hurthle cell (n=1).¹
^§§Number of patients included in the initial efficacy analysis. Efficacy was based on patients who had at least 6 months of follow-up.¹⁰
^||||Patients in this cohort received prior systemic therapies with a median of 2 prior systemic therapies (range 0-9).¹

BID=twice daily; CI=confidence interval; CR=complete response; DoR=duration of response; NE=not estimable; NSCLC=non-small cell lung cancer; ORR=objective response rate; PO=orally; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; RET=rearranged during transfection.

See full trial results

References: 1. Retevmo (selpercatinib). Prescribing Information. Lilly USA, LLC. 2. Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167. 3. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Non-Small Cell Lung Cancer V5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed December 1, 2022. To view the most recent and complete version of the guidelines, go online to https://www.nccn.org. 4. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Thyroid Carcinoma V3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed December 1, 2022. To view the most recent and complete version of the guidelines, go online to https://www.nccn.org. 5. Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). https://clinicaltrials.gov/ct2/show/NCT03157128. Updated June 9, 2022. Accessed June 14, 2022. 6. Data on File, Lilly USA, LLC, DOF-SE-US-0057. 7. Data on File, Lilly USA, LLC, DOF-SE-US-0058. 8. Data on File, Lilly USA, LLC, DOF-SE-US-0028. 9. Data on File, Lilly USA, LLC, DOF-SE-US-0032. 10. Drilon A, Subbiah V, Gautschi O, et al. Durability of efficacy and safety with selpercatinib in patients with RET fusion+ non-small-cell lung cancer: LIBRETTO-001. Poster presented at: European Lung Cancer Congress; March 30–April 2, 2022. Poster 27P. 11. Subbiah V, Wolf J, Konda B, et al. Tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: a global, multicenter trial update (LIBRETTO-001). Presented at the ASCO Annual Meeting; June 3–7, 2022; Chicago, IL. 12. Data on File, Lilly USA, LLC, DOF-SE-US-0063.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Serious hepatic adverse reactions occurred in 3% of patients treated with Retevmo. Increased aspartate aminotransferase (AST) occurred in 59% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 55% of patients, including Grade 3 or 4 events in 12%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue Retevmo based on the severity.

Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with Retevmo. ILD/pneumonitis occurred in 1.8% of patients who received Retevmo, including 0.3% with Grade 3 or 4 events, and 0.3% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold Retevmo and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose, or permanently discontinue Retevmo based on severity of confirmed ILD.

Hypertension occurred in 41% of patients, including Grade 3 hypertension in 20% and Grade 4 in one (0.1%) patient. Overall, 6.3% had their dose interrupted and 1.3% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate Retevmo in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly thereafter, and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue Retevmo based on the severity.

Retevmo can cause concentration-dependent QT interval prolongation. An increase in QTcF interval to >500 ms was measured in 7% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 20% of patients. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes, and thyroid-stimulating hormone (TSH) at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiating Retevmo and during treatment. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue Retevmo based on the severity.

Serious, including fatal, hemorrhagic events can occur with Retevmo. Grade ≥3 hemorrhagic events occurred in 3.1% of patients treated with Retevmo including 4 (0.5%) patients with fatal hemorrhagic events, including cerebral hemorrhage (n=2), tracheostomy site hemorrhage (n=1), and hemoptysis (n=1). Permanently discontinue Retevmo in patients with severe or life-threatening hemorrhage.

Hypersensitivity occurred in 6% of patients receiving Retevmo, including Grade 3 hypersensitivity in 1.9%. The median time to onset was 1.9 weeks (range: 5 days to 2 years). Signs and symptoms of hypersensitivity included fever, rash and arthralgias or myalgias with concurrent decreased platelets or transaminitis. If hypersensitivity occurs, withhold Retevmo and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). Upon resolution of the event, resume Retevmo at a reduced dose and increase the dose of Retevmo by 1 dose level each week as tolerated until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. Permanently discontinue Retevmo for recurrent hypersensitivity.

Tumor lysis syndrome (TLS) occurred in 0.6% of patients with medullary thyroid carcinoma receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, Retevmo has the potential to adversely affect wound healing. Withhold Retevmo for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of Retevmo after resolution of wound healing complications has not been established.

Retevmo can cause hypothyroidism. Hypothyroidism occurred in 13% of patients treated with Retevmo; all reactions were Grade 1 or 2. Hypothyroidism occurred in 13% of patients (50/373) with thyroid cancer and 13% of patients (53/423) with other solid tumors including NSCLC. Monitor thyroid function before treatment with Retevmo and periodically during treatment. Treat with thyroid hormone replacement as clinically indicated. Withhold Retevmo until clinically stable or permanently discontinue Retevmo based on severity.

Based on data from animal reproduction studies and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman. Administration of selpercatinib to pregnant rats during organogenesis at maternal exposures that were approximately equal to those observed at the recommended human dose of 160 mg twice daily resulted in embryolethality and malformations. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for 1 week after the last dose. There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the last dose.

Slipped capital femoral epiphysis/slipped upper femoral epiphysis in pediatric patients (SCFE/SUFE) occurred in 1 adolescent (3.7% of 27 patients) receiving RETEVMO in LIBRETTO-121. Monitor patients for symptoms indicative of SCFE/SUFE and treat as medically and surgically appropriate.

Severe adverse reactions (Grade 3-4) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were hypertension (20%), diarrhea (5%), prolonged QT interval (4.8%), dyspnea (3.1%), fatigue (3.1%), hemorrhage (2.6%), abdominal pain (2.5%), vomiting (1.8%), headache (1.4%), nausea (1.1%), constipation (0.8%), edema (0.8%), rash (0.6%), and arthralgia (0.3%). Serious adverse reactions occurred in 44% of patients who received Retevmo in LIBRETTO-001. The most frequently reported serious adverse reactions (in ≥2% of patients) were pneumonia, pleural effusion, abdominal pain, hemorrhage, hypersensitivity, dyspnea, and hyponatremia. Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who receive Retevmo in LIBRETTO-121 were vomiting (7%), constipation (7%), increased weight (7%), nausea (3.7%), and hemorrhage (3.7%). Serious adverse reactions occurred in 22% of patients who received Retevmo in LIBRETTO-121. The serious adverse reactions (in 1 patient each) were abdominal infection, abdominal pain, aspiration, constipation, diarrhea, epiphysiolysis, nausea, pneumonia, pneumatosis intestinalis, rhinovirus infection, sepsis, and vomiting.

Fatal adverse reactions occurred in 3% of patients in LIBRETTO-001; fatal adverse reactions included sepsis (n=6), respiratory failure (n=5), hemorrhage (n=4), pneumonia (n=3), pneumonitis (n=2), cardiac arrest (n=2), sudden death (n=1), and cardiac failure (n=1).

Common adverse reactions (all grades) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001, were edema (49%), diarrhea (47%), fatigue (46%), dry mouth (43%), hypertension (41%), abdominal pain (34%), rash (33%), constipation (33%), nausea (31%), headache (28%), cough (24%), vomiting (22%), dyspnea (22%), hemorrhage (22%), arthralgia (21%), and prolonged QT interval (21%). In LIBRETTO-121, common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo were musculoskeletal pain (56%), diarrhea (41%), headache (33%), nausea (30%), vomiting (30%), coronavirus infection (30%), abdominal pain (26%), fatigue (26%), pyrexia (26%), hemorrhage (26%), upper respiratory tract infection (22%), oropharyngeal pain (22%), cough (22%), hypothyroidism (19%), constipation (19%), edema (19%), increased weight (19%), rash (19%), stomatitis (15%), and proteinuria (15%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-001, were increased AST (59%; 11%), decreased calcium (59%; 5.7%), increased ALT (56%; 12%), decreased albumin (56%; 2.3%), increased glucose (53%; 2.8%), decreased lymphocytes (52%; 20%), increased creatinine (47%; 2.4%), decreased sodium (42%; 11%), increased alkaline phosphatase (40%; 3.4%), decreased platelets (37%; 3.2%), increased total cholesterol (35%; 1.7%), increased potassium (34%; 2.7%), decreased glucose (34%; 1.0%), decreased magnesium (33%; 0.6%), increased bilirubin (30%; 2.8%), decreased hemoglobin (28%; 3.5%), and decreased neutrophils (25%; 3.2%). In LIBRETTO-121, the most common Grade 3 or 4 laboratory abnormalities (all grades ≥15%; Grade 3-4) worsening from baseline in patients who received Retevmo were decreased calcium (59%, 7%), increased ALT (56%, 3.7%), increased alkaline phosphatase (52%, 0%), increased AST (48%, 3.7%), decreased albumin (44%, 0%), increased bilirubin (30%, 0%), increased creatinine (22%, 0%), decreased potassium (22%, 3.7%), decreased magnesium (15%, 3.7%), decreased neutrophils (44%, 7%), decreased lymphocytes (24%, 4.8%), decreased platelets (22%, 0%), and decreased hemoglobin (19%, 7%).

Concomitant use of acid-reducing agents decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid concomitant use of proton-pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and locally-acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally-acting antacid).

Concomitant use of strong and moderate CYP3A inhibitors increases selpercatinib plasma concentrations which may increase the risk of Retevmo adverse reactions including QTc interval prolongation. Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dosage as recommended and monitor the QT interval with ECGs more frequently.

Concomitant use of strong and moderate CYP3A inducers decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid coadministration of Retevmo with strong and moderate CYP3A inducers.

Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Retevmo is a P-glycoprotein (P-gp) inhibitor. Concomitant use of Retevmo with P-gp substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with P-gp substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp substrates provided in their approved product labeling.

The safety and effectiveness of Retevmo have not been established in pediatric patients less than 2 years of age. The safety and effectiveness of Retevmo have been established in pediatric patients 2 years of age and older for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate), and locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Monitor open growth plates in pediatric patients. Consider interrupting or discontinuing Retevmo if abnormalities occur.

No dosage modification is recommended for patients with mild to severe renal impairment (estimated Glomerular Filtration Rate [eGFR] ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). A recommended dosage has not been established for patients with end-stage renal disease.

Reduce the dose when administering Retevmo to patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times upper limit of normal [ULN] and any AST). No dosage modification is recommended for patients with mild or moderate hepatic impairment. Monitor for Retevmo-related adverse reactions in patients with hepatic impairment.

Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.

Please see full Prescribing Information for Retevmo.

SE HCP ISI All_29MAY24

INDICATIONS

Retevmo is a kinase inhibitor indicated for the treatment of:

adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test
adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy^*
adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options^*

^*These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Retevmo®

Retevmo: The first precision oncology treatment approved by the FDA for certain RET-driven solid tumors, regardless of type1,2